Damien Luque Paz
Overview
Explore the profile of Damien Luque Paz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Picard A, Bayart S, Deparis M, De Maricourt C, Haro S, Jourdain A, et al.
Eur J Pediatr
. 2025 Feb;
184(2):173.
PMID: 39903357
Conclusion: Physicians insisted on the need for training. Only the accumulation of descriptions of MPNs in children will lead to a better management of these diseases. Considering the small proportion...
2.
Mosnier C, Bellal S, Cottin L, Boyer-Perrard F, Boyer F, Lemoine S, et al.
Blood Adv
. 2025 Jan;
9(6):1303-1311.
PMID: 39820709
Patients with essential thrombocythemia (ET) have a chronic evolution with a risk of hematologic transformation associated with a dismal outcome. Because patients with resistance or intolerance have adverse prognosis, it...
3.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Salit R, et al.
Blood Adv
. 2024 Nov;
9(4):797-807.
PMID: 39561372
The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system...
4.
Boulland M, Aliouat A, Jalaber E, Desmares A, Toujani S, Luque Paz D, et al.
J Mol Diagn
. 2024 Aug;
26(11):1007-1017.
PMID: 39182671
Minimal residual disease (MRD) monitoring plays a pivotal role in the management of hematologic malignancies. Well-established molecular targets, such as PML::RARA, CBFB::MYH11, or RUNX1::RUNX1T1, are conventionally tracked by quantitative RT-PCR....
5.
Voirin E, Bouvier A, Plo I, Durix L, Beucher A, Giraudier S, et al.
Am J Hematol
. 2024 May;
99(8):1644-1646.
PMID: 38752375
No abstract available.
6.
Luque Paz D, Chean D, Tattevin P, Luque Paz D, Bayeh B, Kouatchet A, et al.
Ann Intensive Care
. 2024 Apr;
14(1):66.
PMID: 38662091
Background: Multiple randomized controlled studies have compared numerous antibiotic regimens, including new, recently commercialized antibiotics in the treatment of nosocomial pneumonia (NP). The objective of this Bayesian network meta-analysis (NMA)...
7.
Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, et al.
Blood
. 2024 Mar;
143(24):2490-2503.
PMID: 38493481
Pegylated interferon alfa (pegIFN-α) can induce molecular remissions in patients with JAK2-V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal,...
8.
Bauduin A, Demoy M, Genevieve F, Tuffigo M, Luque Paz D, Boussaroque A
Int J Lab Hematol
. 2024 Feb;
46(4):593-594.
PMID: 38409950
No abstract available.
9.
Aubin L, Vilas Boas R, Daltro de Oliveira R, Le Brun V, Divoux M, Rey J, et al.
Am J Hematol
. 2024 Feb;
99(5):1001-1004.
PMID: 38404143
A low allele burden (i.e., <20%) of the CALR driver mutation is found in 10.8% of CALR-mutated MPNs, mostly in essential thrombocythemia, and correlates with a milder phenotype and a...
10.
Galtier J, Drevon L, Le Bris Y, Giraudier S, Wemeau M, Legros L, et al.
Haematologica
. 2024 Feb;
109(6):1989-1993.
PMID: 38328854
No abstract available.